[{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"VAP-1","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma \/ Kubota Vision Inc"},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ University of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ University of Dundee"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"EB005","moa":"Microbiome","graph1":"Dermatology","graph2":"Discovery","graph3":"Eligo Bioscience","amount2":0.22,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.22,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Eligo Bioscience \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IRAK4\/TrkA","graph1":"Dermatology","graph2":"Discovery","graph3":"Evommune","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Evommune \/ Andera Partners","highestDevelopmentStatusID":"2","companyTruncated":"Evommune \/ Andera Partners"},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Enzyme Therapy","moa":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Revel Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"","sponsorNew":"Revel Pharmaceuticals \/ Kizoo Technology Capital","highestDevelopmentStatusID":"2","companyTruncated":"Revel Pharmaceuticals \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Sequence Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sequence Bio \/ LEO Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sequence Bio \/ LEO Pharma"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Alpaca\u2011derived Nanosized Antibody","moa":"IL-17A","graph1":"Dermatology","graph2":"Discovery","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"ENS-002","moa":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Concerto Biosciences","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Concerto Biosciences \/ Safar Partners","highestDevelopmentStatusID":"2","companyTruncated":"Concerto Biosciences \/ Safar Partners"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.

                          Brand Name : ENS-002

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 02, 2022

                          Lead Product(s) : ENS-002

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : Safar Partners

                          Deal Size : $23.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Lead Product(s) : Alpaca‑derived Nanosized Antibody

                          Therapeutic Area : Dermatology

                          Study Phase : Discovery

                          Sponsor : Max Planck Institute for Multidisciplinary Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : The collaboration aims to generate and develop NanoAbs with the potential to answering needs underserved by currently approved conventional monoclonal antibody therapeutics as the NanoAbs exhibit potential for patient convenience, safety, and clinical ou...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 20, 2022

                          Lead Product(s) : Alpaca‑derived Nanosized Antibody

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : Max Planck Institute for Multidisciplinary Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 07, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : Leo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fib...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 17, 2022

                          Lead Product(s) : Enzyme Therapy

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : Kizoo Technology Capital

                          Deal Size : $8.4 million

                          Deal Type : Financing

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound i...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 09, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : Andera Partners

                          Deal Size : $83.0 million

                          Deal Type : Series A Financing

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in a...

                          Brand Name : EB005

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 11, 2021

                          Lead Product(s) : EB005

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : GSK

                          Deal Size : $224.0 million

                          Deal Type : Collaboration

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conv...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 08, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Discovery

                          Sponsor : University of Dundee

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed